Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

jaffar pharmacy - dexchlorpheniramine maleate - prolonged-release tablets - 6

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 2mg;  ; dexchlorpheniramine maleate 2mg - film coated tablet - 2 mg - active: dexchlorpheniramine maleate 2mg   excipient: lactose monohydrate magnesium stearate maize starch starch active: dexchlorpheniramine maleate 2mg excipient: lactose monohydrate magnesium stearate maize starch starch

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - dexchlorpheniramine maleate 0.4 mg/ml;   - syrup - 2 mg/5ml - active: dexchlorpheniramine maleate 0.4 mg/ml   excipient: apricot flavour 15502857 blood orange flavour sc481962 ethanol menthol methyl hydroxybenzoate ponceau 4r propyl hydroxybenzoate purified water sodium chloride sodium citrate dihydrate sorbitol sucrose - hayfever and year round allergies: sneezing, watery itchy eyes itchy skin from hives, insect bites.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - dexchlorpheniramine maleate, quantity: 2 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; lactose monohydrate; magnesium stearate - polaramine is indicated for symptomatic treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated allergic skin manifestations of urticaria and angioedema. polaramine may relieve itching due to skin conditions such as allergic eczema, pruritus ani, pruritus vulvae, atopic dermatitis, contact dermatitis, insect bites, dermographism and drug reactions, including serum sickness.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - dexchlorpheniramine maleate, quantity: 0.4 mg/ml - oral liquid, solution - excipient ingredients: menthol; sodium chloride; purified water; sodium citrate dihydrate; propyl hydroxybenzoate; ethanol; sucrose; sorbitol solution (70 per cent) (crystallising); methyl hydroxybenzoate; brilliant scarlet 4r; flavour - polaramine is indicated for symptomatic treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated allergic skin manifestations of urticaria and angioedema. skin conditions such as allergic eczema, pruritus ani, pruritus vulvae, atopic dermatitis, contact dermatitis, insect bites, dermographism and drug reactions, including serum sickness, are often relieved by polaramine.

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - dexchlorpheniramine maleate 6mg (overage of 5.5% used during manufacture) - modified release tablet - 6 mg - active: dexchlorpheniramine maleate 6mg (overage of 5.5% used during manufacture) excipient: acacia calcium phosphate calcium sulfate dihydrate carnauba wax colophony gelatin soap: schering-plough company monograph lactose monohydrate magnesium stearate maize starch methyl hydroxybenzoate oleic acid purified talc sucrose white beeswax zein

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - dexchlorpheniramine maleate - tablet, sugar coated - 6 mg